Lack of association of Ang-2 levels during active AAV with response to treatment in the RAVE trial.

*Primary Endpoint = completed month 6 per study protocol, in remission and not on prednisone. Remission = in remission at month 6 regardless of whether primary endpoint was met. Flare = worsening disease, or active disease following a period of remission, during the first six months of treatment.
†Numbers fulfilling and not fulfilling the criteria in column one.
‡Serum Ang-2 (ng/ml) in subjects fulfilling (Yes) and not fulfilling (No) the criteria in column one; medians and interquartile ranges are shown.